Serum Tumor Marker Use in Patients With Advanced Solid Tumors
Serum Tumor Marker Use in Patients With Advanced Solid Tumors
复制标题
DOI：
10.1200/jop.2015.005660
复制
发表时间：
2016-01-01
影响因子：
--
通讯作者：
Hershman, Dawn L.
中科院分区：
文献类型：
--
作者：
Accordino, Melissa K.;Wright, Jason D.;Hershman, Dawn L.
目的晚期实体瘤患者血清肿瘤标志物检测的频率存在很大差异。我们进行了一项回顾性分析，以评估血清肿瘤标志物use.MethodsPatients诊断为晚期癌症与门诊就诊之间的2013年7月1日，2014年6月30日，在一个单一的中心。根据国际疾病分类第九次修订版编码确定肿瘤和分期，并通过肿瘤登记和病历审查进行确认。对于每一个病人，我们记录了以下肿瘤标志物的日期：甲胎蛋白，CA-125，CA 15-3，CA 19-9，CA 27-29和癌胚抗原。我们评估了每例患者超过12个月的测试数量和每例患者每月的最大测试数量。每例患者的任何单独测试的平均数量为7次测试，最大数量为35次测试;每例患者的总测试的平均数量为12次测试，最大数量为70次测试; 16.3%的患者每年进行超过12次单独测试。在1个月的时间内，34.3%的患者进行了一次以上的单独测试。CA 19-9和癌胚抗原是最常见的过度使用的tests.ConclusionWe发现了一个高比率的血清肿瘤标志物检测使用在晚期实体瘤患者。鉴于癌症治疗费用的增加，应努力确定血清肿瘤标志物在晚期实体瘤患者随访治疗中的益处。
PurposeThere is substantial variability in the frequency of serum tumor marker testing in patients with advanced solid tumors. We performed a retrospective analysis to evaluate the frequency of serum tumor marker use.MethodsPatients with a diagnosis of advanced cancer with outpatient visits between July 1, 2013, and June 30, 2014, at a single center were included. Tumor and stage were determined by International Classification of Diseases, Ninth Revision codes and confirmed with tumor registry and medical record review. For each patient, we recorded the dates of each of the following tumor markers: a-fetoprotein, CA-125, CA 15-3, CA 19-9, CA 27-29, and carcinoembryonic antigen. We evaluated the number of tests per patient over 12 months and the maximum number of tests per patient per month.ResultsWe included 928 patients in the analysis. The mean number of any individual test per patient was seven tests, and the maximum number was 35 tests; the mean number of total tests per patient was 12 tests, and the maximum number was 70 tests; 16.3% of patients had more than 12 individual tests per year. In a 1-month span, 34.3% of patients had more than one individual test. CA 19-9 and carcinoembryonic antigen were the most commonly overused tests.ConclusionWe found a high rate of serum tumor marker testing use in patients with advanced solid tumors. Given the increasing costs of cancer care, efforts should be made to determine the benefit of serum tumor markers in thefollow-up care of patientswith advanced solid tumors.